{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Marrow Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hematological Improvement"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Failure"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Responses assessed by the International Working Group (IWG) 2023 criteria are a set of standardized guidelines used to assess treatment response in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These criteria are designed to evaluate a patient's response based on hematologic improvements, such as changes in blood counts and transfusion independence.","groups":[{"description":"Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nDecitabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRecombinant EphB4-HSA Fusion Protein: Given IV","id":"OG000","title":"Treatment (sEphB4-HSA, Azacitidine, Decitabine)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who completed at least 2 cycles were assessed for response.","reportingStatus":"POSTED","timeFrame":"Up to 56 days (2 courses of protocol treatment)","title":"Overall Response Defined as the Occurrence of Complete Response, Marrow Complete Response, Partial Response, or Hematological Improvement","type":"PRIMARY","unitOfMeasure":"Participants"}